Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Adaptimmune Therapeutics PlcADAP-2.050.856.09-10.15-65.04%8.15%50.08$0.68-$0.1813,869$0.58

Detail of Adaptimmune Therapeutics Plc

 
CEO
Mr. Adrian G. Rawcliffe
Employees
449
Industry
Biotechnology
Sector
Healthcare
Market cap
$148M

Company details

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Revenue
Revenue (Rev)
$175.04M
Adaptimmune Therapeutics Plc
ADAP • XNGS • US
$0.58
+0.09 (18.85%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.28
Margin profit
-51.25%
52 week low
$0.441
52 week high
$1.75
50-day simple moving average
$0.66
200-day simple moving average
$0.68
Percent held by insiders
0.38%
Percent held by institutions
60.27%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
ADAP +28.89%
eps change
ADAP 0.00%